Clinical trials: Dependence
Nicotine Dependence, Major Depressive Disorder
Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers
Persons who struggle with depression smoke at high rates and experience low quit rates in treatment. The best way to improve cessation treatment for this underserved population remains unknown.
- Trial name
- NCT02378714
- Testing
- Varenicline, BASC, Standard treatment
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Northwestern University
Nicotine Dependence
Nicotine Vaccination and Nicotinic Receptor Occupancy
This is a molecular imaging research study designed to examine how much nicotine gets into the brain before and after vaccination with NicVAX, a nicotine vaccine developed by Nabi Biopharmaceuticals.
- Trial name
- NCT00996034
- Testing
- NicVAX, [123I]5-IA-85380, Nicotine bitartrate
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Yale University
Opiate Dependence
Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence
The aim of the study is to determine whether buprenorphine/naloxone maintenance versus detoxification using buprenorphine/naloxone, in prescription opioid dependent patients receiving primary care management and drug counseling…
- Trial name
- NCT00555425
- Testing
- Behavioral: Buprenorphine/naloxone maintenance (Mtn), Behavioral: Buprenorphine/naloxone detoxification (Dtx)
- Where
- 2 sites in United States
- Volunteers
- 113 people
- Sponsor
- Yale University
Alcohol Dependence, Chronic Hepatitis C
Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients
The purpose of this study is to determine whether motivational enhancement therapy (MET) reduces alcohol use in a population of HCV-infected veterans who are currently drinking alcohol and have alcohol disorders.
- Trial name
- NCT00596960
- Testing
- Motivational Enhancement Therapy (MET), Health education
- Where
- 2 sites in United States
- Volunteers
- 139 people
- Sponsor
- US Department of Veterans Affairs
Cigarette Smoking, Nicotine Dependence
Incentives for Oklahoma Tobacco Helpline Engagement in Persistent Poverty Counties
The proposed pilot project is designed to evaluate the feasibility and potential efficacy of offering small financial incentives for the completion of smoking cessation counseling and self-reported abstinence at follow-up among…
- Trial name
- CLIMB (NCT05095779)
- Testing
- Coaching calls, Nicotine replacement therapy, Financial Incentives
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- University of Oklahoma
Substance Use Disorders, Alcohol Abuse
Reinforcement of Abstinence and Continuing Care in Substance Abuse Treatment
The Contracts, Prompts, and Social Reinforcement (CPR) intervention was designed to address the continuing care adherence needs of veterans presenting for substance use disorder (SUD) treatment.
- Conditions
- Substance Use Disorders, Alcohol Abuse, Alcoholism, Substance Dependence
- Trial name
- NCT00288886
- Testing
- Contracting, Prompting and Reinforcement arm, Control arm
- Where
- 2 sites in United States
- Volunteers
- 183 people
- Sponsor
- US Department of Veterans Affairs
Cocaine Dependence
Progesterone Treatment for Cocaine-dependent Women: A Pilot Study
The purpose of this pilot treatment trial is to evaluate the efficacy of oral micronized PROG in cocaine-dependent women. Since we have shown (Evans \& Foltin, 2006) that oral micronized PROG attenuates the positive subjective…
- Trial name
- PROG (NCT00632099)
- Testing
- Oral micronized progesterone
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- New York State Psychiatric Institute
Opioid Dependence, on Agonist Therapy
Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence
The purpose of this study was to assess safety, efficacy, and treatment retention following extended treatment with OX219, a higher-bioavailability buprenorphine/naloxone (BNX) sublingual tablet formulation in opioid-dependent…
- Trial name
- NCT01903005
- Testing
- Higher bioavailability BNX sublingual tablets
- Where
- 28 sites in United States
- Volunteers
- 668 people
- Sponsor
- Orexo AB
HIV Infections, Opioid-Related Disorders
Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users
Drug abuse and HIV/AIDS are serious global health problems. Injection drug use is currently the major mode of transmission of HIV in many countries.
- Trial name
- NCT00270257
- Testing
- Buprenorphine/Naloxone
- Where
- 4 sites in China, Thailand
- Volunteers
- 1,251 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Smoking, Tobacco Dependence
Varenicline Treatment for Active Alcoholic Smokers
Alcohol dependence is a significant and prevalent public health problem affecting approximately 4% of the U.S. adult population.
- Conditions
- Smoking, Tobacco Dependence, Alcohol Dependence
- Trial name
- NCT01347112
- Testing
- Varenicline
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Severe Mental Illness, Nicotine Dependence
Electronic Decision Support Systems for Smokers With Severe Mental Illness
This randomized clinical trial among SMI smokers assessed whether the EDSS with carbon monoxide monitor and health-checklist feedback lead to higher rates of initiation of smoking cessation treatment, days of smoking abstinence…
- Conditions
- Severe Mental Illness, Nicotine Dependence, Schizophrenia, Tobacco Use Disorder
- Trial name
- NCT01412866
- Testing
- EDSS with CO feedback and health checklist, EDSS with health checklist feedback alon
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Smoking, Nicotine Dependence
Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain
This study will test a combination of the drugs naltrexone and bupropion with weight-concerned smokers to investigate whether or not this combination of drugs improves smoking cessation quit rates and minimizes post quit weight…
- Trial name
- NCT00129246
- Testing
- Naltrexone, Bupropion
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Yale University
Nicotine Dependence
Effects of Varenicline on Smoking Reminders
Varenicline is the best smoking cessation agent to date; however it is only effective in a subgroup of smokers and is associated with undesirable side effects in other subgroups.
- Trial name
- VSMK (NCT01524627)
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- University of Pennsylvania
Smoking, Smoking Cessation
Identifying Optimal Smoking Cessation Intervention Components (Cessation)
The goal of this research is to identify the best smoking cessation intervention components to be combined into a state-on-the-art, comprehensive smoking cessation intervention.
- Conditions
- Smoking, Smoking Cessation, Nicotine Dependence
- Trial name
- Cessation (NCT01116986)
- Testing
- Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive in-person counseling during the quit attempt
- Where
- United States
- Volunteers
- 637 people
- Sponsor
- University of Wisconsin, Madison
Opioid Abuse, Opioid Dependence
A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals
Buprenorphine is an approved medication for the treatment of opioid dependence. It is typically administered once daily as a sublingual tablet combined with naloxone (i.e., Suboxone).
- Trial name
- NCT01136356
- Testing
- buprenorphine, morphine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Johns Hopkins University
Cocaine Dependence
The Effect of Glutamatergic Modulation on Cocaine Self-administration
Repeated drug consumption may progress to problematic use by triggering neuroplastic adaptations that attenuate sensitivity to natural rewards while increasing reactivity to craving and drug cues.
- Trial name
- NCT02596022
- Testing
- CI-581a, CI-581b
- Volunteers
- 18 people
- Sponsor
- New York State Psychiatric Institute
Smokeless Tobacco Use, Tobacco Dependence
Novel Determinants and Measures of Smokeless Tobacco Use: Study 1
The extent of toxicity varies considerably across different brands of smokeless tobacco (ST) products and data suggest that greater toxicity may result in greater health risks.
- Trial name
- NCT01067586
- Where
- 3 sites in United States
- Volunteers
- 359 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Colorectal Cancer, Squamous Cell Head and Neck Cancer
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.
- Conditions
- Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT01451632
- Testing
- MM-121, Irinotecan, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Merrimack Pharmaceuticals
Depressive Disorder, Major, Cannabis Abuse
Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence
Adolescents who are diagnosed with major depressive disorder are often also diagnosed with marijuana dependence. Fluoxetine is an antidepressant medication currently used to treat young people who are diagnosed with major…
- Trial name
- CADY (NCT00149643)
- Testing
- Fluoxetine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Pittsburgh
Cocaine Dependence, Cocaine Abuse
Quetiapine for the Reduction of Cocaine Use
This placebo-controlled trial will test the effectiveness of Seroquel XR™ for the treatment of cocaine dependence in non-psychotic individuals who are cocaine dependent.
- Conditions
- Cocaine Dependence, Cocaine Abuse, Cocaine Addiction, Drug Abuse
- Trial name
- AZC (NCT00631748)
- Testing
- quetiapine fumarate, Cognitive-behavioral Therapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research